Chugai Pharmaceutical Co. (OTCMKTS:CHGCY)’s stock price dropped 3.8% during trading on Tuesday . The stock traded as low as $207.33 and last traded at $210.96, approximately 7,329 shares traded hands during trading. An increase of 43% from the average daily volume of 5,121 shares. The stock had previously closed at $219.32.
Separately, Jefferies Financial Group initiated coverage on shares of Chugai Pharmaceutical in a research report on Monday, December 9th. They set a “buy” rating on the stock.
The business has a 50-day moving average price of $212.49.
Chugai Pharmaceutical Company Profile (OTCMKTS:CHGCY)
Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research and development, manufacture, marketing, and distribution of prescription medicines in Japan and internationally. The company's products for oncology primarily include Avastin, Herceptin, Rituxan, Alecensa, Perjeta, Xeloda, Tarceva, Kadcyla, Zelboraf, Neutrogin, Tecentriq, and Gazyva; bone and joint diseases/autoimmune diseases comprise Actemra, Edirol, Suvenyl, and Bonviva; renal diseases consist of Mircera and Oxarol; and transplant, immunology, infectious, and other diseases comprise Tamiflu, CellCept, Copegus, and Hemlibra.
Further Reading: 52- Week Highs
Receive News & Ratings for Chugai Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chugai Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.